1. Search Result
Search Result
Results for "

adrenocortical

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

2

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16276
    Osilodrostat
    4 Publications Verification

    LCI699

    Mineralocorticoid Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) .
    Osilodrostat
  • HY-13690
    Mitotane
    5 Publications Verification

    2,4′-DDD; o,p'-DDD

    Apoptosis Cancer
    Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
    Mitotane
  • HY-153367
    FHD-609
    2 Publications Verification

    PROTACs Epigenetic Reader Domain Cancer
    FHD-609 is a PROTAC degrader and inhibitor of BRD9 (Bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment. (Blue: BRD9 ligand-6 (HY-49393), Black: linker (HY-168309); Pink: (S)-Deoxy-thalidomide-Br (HY-168308) ) .
    FHD-609
  • HY-B1214

    Prednisolone 21-acetate

    Glucocorticoid Receptor Inflammation/Immunology Cancer
    Prednisolone acetate (Prednisolone 21-acetate) is an adrenocortical hormone active molecule with various pharmacological effects such as anti-inflammatory, anti-allergic, and immune suppression.
    Prednisolone acetate
  • HY-N0417
    Cucurbitacin E
    5+ Cited Publications

    α-Elaterin; α-Elaterine

    CDK Autophagy PANoptosis Metabolic Disease Inflammation/Immunology Cancer
    Cucurbitacin E is a CDK1 inhibitor that significantly inhibits the activity of the cyclin B1/CDC2 complex. Cucurbitacin E also induces PANoptosis in adrenocortical carcinoma cells in a ZBP1-dependent manner. Cucurbitacin E exhibits synergistic effects with Mitotane (HY-13690); when used in combination, they effectively eliminate tumors .
    Cucurbitacin E
  • HY-110042

    HSP Apoptosis CDK PERK Metabolic Disease Inflammation/Immunology Cancer
    CCT018159 is an ATP-competitive HSP90β inhibitor, with an IC50 of 3.2 μM against human HSP90β ATPase and 6.6 μM against yeast HSP90β ATPase. CCT018159 induces cell cycle arrest and apoptosis in tumor cells, and inhibits invasion and angiogenesis. CCT018159 is applicable to cancer-related research .
    CCT018159
  • HY-16276A
    Osilodrostat phosphate
    4 Publications Verification

    LCI699 phosphate

    Mineralocorticoid Receptor Cardiovascular Disease Cancer
    Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. Osilodrostat phosphate has blood pressure lowering ability. Osilodrostat phosphate can be used for research of Cushing syndrome (CS) .
    Osilodrostat phosphate
  • HY-100399
    Nevanimibe
    3 Publications Verification

    PD-132301; ATR-101

    Acyltransferase Apoptosis Cancer
    Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer .
    Nevanimibe
  • HY-100399A
    Nevanimibe hydrochloride
    3 Publications Verification

    PD-132301 hydrochloride; ATR101 hydrochloride

    Acyltransferase Apoptosis Cancer
    Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .
    Nevanimibe hydrochloride
  • HY-P10762

    CBP-1008; LDC 10B

    Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    Ricorfotide vedotin
  • HY-B1618S
    Corticosterone-d8
    1 Publications Verification

    Isotope-Labeled Compounds Glucocorticoid Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Corticosterone-d8 is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
    Corticosterone-d8
  • HY-108618
    BC11-38
    2 Publications Verification

    Phosphodiesterase (PDE) Endocrinology
    BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC50s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells .
    BC11-38
  • HY-134462

    Orphan Nuclear Receptor Metabolic Disease Cancer
    RJW103 is an acid-stable SF-1 (NR5A1) and LRH-1 agonist with pEC50 values of 6.5 and 5.9, respectively. RJW103 activates SF-1- and LRH-1-mediated transcription of endogenous target genes. RJW103 can be used in research on cancer, endocrinology and metabolic diseases, such as adrenocortical tumors .
    RJW103
  • HY-107939

    Glucocorticoid Receptor Cytochrome P450 Neurological Disease Metabolic Disease Inflammation/Immunology
    Paramethasone Acetate is an orally active long-acting glucocorticoid. Paramethasone Acetate directly inhibits testicular aromatase, thereby reducing the synthesis of estradiol. Paramethasone Acetate suppresses the basal and midcycle luteinizing hormone surges in female animals and blocks estrogen synthesis. Paramethasone Acetate also decreases circulating levels of dihydrotestosterone, androstenedione and estradiol in male animals. Paramethasone Acetate inhibits cartilage degeneration and alleviates joint pathological damage in osteoarthritis models. Paramethasone Acetate can be used in research related to osteoarthritis and endocrinology .
    Paramethasone Acetate
  • HY-B1618S1

    17-Deoxycortisol-d4; 11β,21-Dihydroxyprogesterone-d4; Kendall's compound B-d4

    Isotope-Labeled Compounds Glucocorticoid Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Corticosterone-d4 is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
    Corticosterone-d4
  • HY-13690R

    2,4′-DDD (Standard); o,p'-DDD (Standard)

    Reference Standards Apoptosis Cancer
    Mitotane (Standard) is the analytical standard of Mitotane. This product is intended for research and analytical applications. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
    Mitotane (Standard)
  • HY-134462A

    Orphan Nuclear Receptor Cancer
    RJW103 TFA is an acid-stable SF-1 (NR5A1) and LRH-1 agonist with pEC50 values of 6.5 and 5.9, respectively. RJW103 TFA activates SF-1- and LRH-1-mediated transcription of endogenous target genes. RJW103 TFA can be used in research on cancer, endocrinology and metabolic diseases, such as adrenocortical tumors .
    RJW103 TFA
  • HY-123586

    MEK VEGFR FLT3 PDGFR Cancer
    L-783277 (Compound 4) is a MEK inhibitor (IC50 = 4 nM). L-783277 has potent inhibitory activity against a variety of kinases, including VEGFR2/3, FLT1/3/4, MEK1/2, KDR, and PDGFRα, but has low selectivity for the kinase community. L-783277 inhibits viability (IC50 = 22 mM) and cell proliferation (IC50 = 21 mM) of H295R cells. L-783277 could be used in research on cancers such as adrenocortical carcinoma .
    L-783277
  • HY-13690S1

    2,4′-DDD-13C6; o,p'-DDD-13C6

    Apoptosis Cancer
    Mitotane- 13C6 is the 13C labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
    Mitotane-13C6
  • HY-13690S3

    2,4′-DDD-13C12; o,p'-DDD-13C12

    Isotope-Labeled Compounds Apoptosis Cancer
    Mitotane- 13C12 (2,4′-DDD- 13C12) is 13C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
    Mitotane-13C12
  • HY-100399AR

    PD-132301 hydrochloride (Standard); ATR101 hydrochloride (Standard)

    Reference Standards Acyltransferase Apoptosis Cancer
    Nevanimibe hydrochloride (Standard) is the analytical standard of Nevanimibe hydrochloride. This product is intended for research and analytical applications. Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .
    Nevanimibe hydrochloride (Standard)
  • HY-W1124386

    SNAP-DBCO

    Drug Intermediate Drug Derivative Cancer
    BG-DBCO is a DBCO-conjugated Benzylguanine. BG-DBCO, SNAP-E3 fusion protein and Ligand-N3 form a protein complex. BG-DBCO is conjugated with JQ1-N3-C10 to obtain BG-JQ1. BG-JQ1, administered together with SIAH1-SN mRNA, effectively inhibits the growth of small cell carcinoma of the adrenocortical gland .
    BG-DBCO
  • HY-117127

    AY-11440

    Progesterone Receptor Others
    Clogestone acetate (AY-11440) is an orally active progesterone receptor agonist. Clogestone acetate reduces adrenal and ovarian weight, as well as serum and adrenocortical ketone levels in rats .
    Clogestone acetate
  • HY-N6629R

    Neuromedin U Receptor (NMUR) Reference Standards Neurological Disease
    Prednisolone acetate (Standard) is the analytical standard of Prednisolone acetate. This product is intended for research and analytical applications. Prednisolone acetate (Prednisolone 21-acetate) is an adrenocortical hormone active molecule with various pharmacological effects such as anti-inflammatory, anti-allergic, and immune suppression.
    3'-Methoxyflavonol (Standard)
  • HY-B1214R

    Prednisolone 21-acetate (Standard)

    Reference Standards Glucocorticoid Receptor Inflammation/Immunology Cancer
    Prednisolone acetate (Standard) is the analytical standard of Prednisolone acetate. This product is intended for research and analytical applications. Prednisolone acetate (Prednisolone 21-acetate) is an adrenocortical hormone active molecule with various pharmacological effects such as anti-inflammatory, anti-allergic, and immune suppression.
    Prednisolone acetate (Standard)
  • HY-13690S2

    2,4′-DDD-d8; o,p'-DDD-d8

    Apoptosis Cancer
    Mitotane-d8 is the deuterium labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
    Mitotane-d8
  • HY-16276R

    LCI699 (Standard)

    Mineralocorticoid Receptor Reference Standards Cardiovascular Disease Inflammation/Immunology Cancer
    Osilodrostat (Standard) is the analytical standard of Osilodrostat. This product is intended for research and analytical applications. Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) .
    Osilodrostat (Standard)
  • HY-108618R

    Reference Standards Phosphodiesterase (PDE) Endocrinology
    BC11-38 (Standard) is the analytical standard of BC11-38 (HY-108618). This product is intended for research and analytical applications. BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC50s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells .
    BC11-38 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: